Filtered By:
Condition: Thrombocytopenia
Education: Study

This page shows you your search results in order of date.

Order by Relevance | Date

Total 203 results found since Jan 2013.

PAD4-Induced NETosis Via Cathepsin G-Mediated Platelet-Neutrophil Interaction in ChAdOx1 Vaccine-Induced Thrombosis
CONCLUSIONS: Patients with VITT display enhanced thrombogenesis by PAD4-mediated NETs formation via cathepsin G-mediated platelet/neutrophil interaction.PMID:37586040 | DOI:10.1161/ATVBAHA.123.319522
Source: Arteriosclerosis, Thrombosis and Vascular Biology - August 16, 2023 Category: Cardiology Authors: Roberto Carnevale Martina Leopizzi Marcello Dominici Giulia d'Amati Simona Bartimoccia Cristina Nocella Vittoria Cammisotto Alessandra D'Amico Valentina Castellani Francesco Baratta Alessia Bertelli Alessio Arrivi Danilo Toni Manuela De Michele Pasquale P Source Type: research

Outcomes After Decompressive Surgery for Severe Cerebral Venous Sinus Thrombosis Associated or Not Associated with Vaccine-Induced Immune Thrombosis with Thrombocytopenia: A Multicenter Cohort Study
ConclusionsAlthough the prediction of individual courses remains challenging, DS should be considered early in VITT-associated CVST because an overall favorable outcome appears achievable in these patients.
Source: Neurocritical Care - July 27, 2023 Category: Neurology Source Type: research

Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
CONCLUSIONS: Anlotinib combined with temozolomide is efficacious and tolerated in recurrent GBM patients.PMID:37477938 | DOI:10.1158/1078-0432.CCR-23-0388
Source: Clinical Cancer Research - July 21, 2023 Category: Cancer & Oncology Authors: Qingsheng Xu Kaiyuan Huang Xiangqi Meng Yuxiang Weng Luyuan Zhang Linghao Bu Xiujue Zheng Jinquan Cai Renya Zhan Qun Chen Source Type: research

Cerebral infarction and in-hospital mortality for patients admitted to hospital with intracardiac thrombus: insights from the National Inpatient Sample
Abstract The factors associated with cerebral infarction and mortality in patients hospitalized with intracardiac thrombus are unknown. A retrospective cohort study was undertaken of nationally representative hospital admissions in the National Inpatient Sample with a diagnosis of intracardiac thrombus between 2016 to 2019. Multiple logistic regressions were used to define factors associated with cerebral infarction and in-hospital mortality. There were a total of 175,370 admissions for patients with intracardiac thrombus and 10.1% patients had cerebral infarction (n  = 17,675). Intracardiac thrombus represented 4.4%...
Source: Journal of Thrombosis and Thrombolysis - June 5, 2023 Category: Hematology Source Type: research

Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: The Last 10 Years
Semin Thromb Hemost DOI: 10.1055/s-0043-1769013Current guideline recommendations for primary prophylaxis of venous thromboembolism (VTE) are based on randomized clinical trials that usually exclude subjects at a potentially high risk of bleeding complications. For this reason, no specific guideline is available for thromboprophylaxis in hospitalized patients with thrombocytopenia and/or platelet dysfunction. However, except in patients with absolute contraindications to anticoagulant drugs, antithrombotic prophylaxis should always be considered, for example, in hospitalized cancer patients with thrombocytopenia, especially...
Source: Seminars in Thrombosis and Hemostasis - May 18, 2023 Category: Hematology Authors: Tufano, Antonella Brenner, Benjamin Tags: Review Article Source Type: research

Medically Attended Acute Adverse Events in Pregnant People After Coronavirus Disease 2019 (COVID-19) Booster Vaccination
Obstet Gynecol. 2023 May 11. doi: 10.1097/AOG.0000000000005241. Online ahead of print.ABSTRACTIn this multisite, observational, matched cohort study of more than 80,000 pregnant people, receipt of an mRNA monovalent coronavirus disease 2019 (COVID-19) booster vaccination in pregnancy was not associated with increased risk for thrombocytopenia, myocarditis, venous thromboembolism, ischemic stroke, or other serious adverse events within 21 or 42 days after booster vaccination. The mRNA monovalent COVID-19 booster in pregnancy was associated with an increased risk for medically attended malaise or fatigue within 7 days of vac...
Source: Obstetrics and Gynecology - May 11, 2023 Category: OBGYN Authors: Malini B DeSilva Jacob Haapala Gabriela Vazquez-Benitez Thomas G Boyce Candace C Fuller Matthew F Daley Darios Getahun Simon J Hambidge Heather S Lipkind Allison L Naleway Jennifer C Nelson Kimberly K Vesco Eric S Weintraub Joshua T B Williams Ousseny Zer Source Type: research